MBS is proud to have MAB206P, monoclonal antibody to polyethylene glycol (PEG) entered into a commercially available ELISA for drug development.  MAB206P, anti-PEG IgG3 antibody was developed in Balb/c mice also immunized with the 5 kDa PEG conjugated to KLH using the MBS rapid immunization protocol.  The best performing fusion product was selected using the same criteria listed above for subcloning, production and purification.  The monoclonal antibody is produced in vitro and purified using protein A.  By indirect ELISA, it recognizes 20 kD.  This and one additional monoclonal antibody to PEG are available for sampling at sales@mainebiotechnology.com

Preliminary Technical Data 

In an effort to support our customers working with recombinant antigens, MBS developed a mouse monoclonal antibody against a polyhistidine (HIS) tag.  After meeting all the following development goals;  antibody with a high affinity, function in Western Blot, a strong sensitivity and a seamless efficient production rate, MBS offers MAB230P.

Western Blot against 6X-HIS-ProIS5.  Antigen titration is at 100 ng,  25 ng, 5 ng / ml 

 
MAB230P, Monoclonal antibody to  polyhistidine (HIS) tag, has demonstrated an apparent affinity of 8.85 x 10^-12, able to detect HIS tagged antigen at picomolar concentrations (as determined by Forte Bio Octet Red)

 Indirect ELISA for the 4X-HIS:BSA conjugate

Yes, MBS has always offered anti-id Hybridoma development services.  In the past 2 years we have seen a significant increase in the number of requests as a result of the increase in antibody based therapies.  As novel humanized antibodies move through validation, the ability to identify the CDR regions (idiotype) of the drug antibody is critical.  MBS is proud to say that many of the antibodies developed for our pharmaceutical customers are currently being used in active clinical trials.   There is not a one size fits all solution or special protocol for making anti-idiotypic antibodies.  Instead, it’s the careful planning of experienced hybridoma development experts, tools to refine clone selection such as MultiPure and Octet Red, and communication with customers that has resulted in a very high level of success for anti-idiotypic projects.  Experience is the most important element in an anti-id project.  With approximately 1 in 4 of new hybridoma development projects having an anti-id goal, we are able to convey a high level of confidence to customers for these crucial, time sensitive projects. 

Contact us for a custom quote today.

Introducing MAB223P and MAB224, Monoclonal antibodies to human Norovirus GII.4

Noroviruses from genogroup II, genotype four (GII.4) are responsible for the majority of adult outbreaks of gastroenteritis. Two new GII.4 variants caused the majority of Norovirus outbreaks.

The research and development group at MBS used  rVLP GII.4 2006 Minerva strain as an immunogen to develop a panel of antibodies that would also be broadly cross reactive within the GII group.  MAB223P and MAB224P are the first clones from the project to be added to the product catalog.  They demonstrate good reactivity against time-ordered antigens.

MAB223P and MAB224P are ready and available for sampling.  Contact us to reserve your sample today.  Look for more Norovirus antibodies of interest to be added to the catalog soon!

New Control Antibodies to Human Ig Isotypes are available from MBS R&D. We are now offering: Fc, IgA, IgM, IgG1, IgG2, IgG3, IgG4, Kappa, and Lambda. Antibodies to murine isotypes, previously developed by MBS R&D are also available.  Contact us for sampling information.

The VPAC-1 receptor recently made news as a therapeutic target for patients undergoing cheomotherapy http://www.thrombogenics.com/html/pipeline6B.asp.  MBS has a Multipure plate of antibodies recognizing VPAC-1 available for sampling.  Contact us to order yours.

MBS R&D is introducing two new anti-human Myeloperoxidase monoclonal antibodies.   Contact us  to order the two antibodies recognizing Myeloperoxidase (MPO), a well documented biomarker for immune deficiency and myocardial infarction. The antibodies were developed in-house and validated as a matched pair in a sandwich ELISA format

 The greatest sensitivity is observed when using MAB208P as the capture antibody and MAB209P conjugated to biotin as the tracer antibody.  This pair is able to detect MPO at <3 ng/ml under these assay conditions.   In addition MAB208P and MAB209P are capable of self pairing, with the MAB209P self pair able to detect MPO at 6 ng/ml. The versatility of these monoclonal antibodies adds to their value and potential use for quantitative Myeloperoxidase assays.

MAB208P

MAB209P

Maine Biotechnology Services has developed two antibodies that recognize the linear backbone of Polyethylene glycol (PEG). There are broad applications for these antibodies in both production and R&D settings. Our PEG antibodies can be a vital tool for propelling therapeutics to market by serving as a positive control anti-drug antibody, measuring clearance of a drug, or simply in a western blot as a QA release confirming PEGylation.

Click Here for More Information on PEG Antibodies